In a Washington Post opinion piece, Dartmouth’s Lisa Schwartz and Steven Woloshin say the Food and Drug Administration is “finally pushing back against the over-prescribing of testosterone.

“Last month, in response to new FDA rules, testosterone manufacturers released new instructions for doctors making it clear that testosterone is not approved for ‘low-T’— a marketing term developed by drug companies to describe men with low testosterone levels caused by aging. Companies must now warn doctors about a possible increased risk of heart attack and stroke in men who take these drugs,” write Schwartz and Woloshin, who are both professors of community and family medicine at the Geisel School of Medicine and The Dartmouth Institute for Health Policy and Clinical Practice.

Read the full opinion piece, published 6/7/15 by The Washington Post.